Purpose The purpose of this study is to investigate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and plasma cytokines and angiogenic factors (CAFs) as pharmacodynamic and prognostic biomarkers of bevacizumab monotherapy in colorectal cancer with liver metastasis (CRCLM). Materials and Methods From July 2011 to March 2012, 28 patients with histologically confirmed CRCLM received bevacizumab monotherapy followed by combined FOLFOX therapy. The mean age of the patients was 57 years (range, 30 to 77 years). DCE-MRI (Ktransand IAUC60) was performed at baseline, first follow-up (3 days after bevacizumab monotherapy), and second follow-up (3 days after combined therapy). CAF levels (vascular endothelial growth factor [VEGF], placental growth factor [PlGF], and interleukin-8) were assessed on the same days. Progression-free survival (PFS) time distributions were summarized using the Kaplan-Meier method and compared using log-rank tests.
Results The median PFS period was 11.2 months. Ktrans, IAUC60, VEGF, and PlGF values on the first follow-up day were significantly different compared with baseline values. No differences were observed on the second follow-up day. A > 40% decrease in Ktrans from baseline to first follow-up was associated with a longer PFS (hazard ratio, 0.349; 95% confidence interval, 0.133 to 0.912; p=0.032). Changes in CAFs did not show correlation with PFS time. Conclusion DCE-MRI parameters and CAFs are pharmacodynamic biomarkers of bevacizumab for CRCLM. In our study, change in Ktrans at 3 days after bevacizumab monotherapy was a favorable prognostic factor; however, the value of CAFs as a prognostic biomarker was not found.
Citations
Citations to this article as recorded by
Decoding Tumor Angiogenesis for Therapeutic Advancements: Mechanistic Insights Geetika Kaur, Bipradas Roy Biomedicines.2024; 12(4): 827. CrossRef
Current trends in the characterization and monitoring of vascular response to cancer therapy Binita Shrestha, Noah B Stern, Annie Zhou, Andrew Dunn, Tyrone Porter Cancer Imaging.2024;[Epub] CrossRef
Role of advanced imaging techniques in the evaluation of oncological therapies in patients with colorectal liver metastases Martina Caruso, Arnaldo Stanzione, Anna Prinster, Laura Micol Pizzuti, Arturo Brunetti, Simone Maurea, Pier Paolo Mainenti World Journal of Gastroenterology.2023; 29(3): 521. CrossRef
Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition Brandon M. Bordeau, Joseph Ryan Polli, Ferdinand Schweser, Hans Peter Grimm, Wolfgang F. Richter, Joseph P. Balthasar International Journal of Molecular Sciences.2022; 23(2): 679. CrossRef
The cancer angiogenesis co-culture assay: In vitro quantification of the angiogenic potential of tumoroids Sarah Line Bring Truelsen, Nabi Mousavi, Haoche Wei, Lucy Harvey, Rikke Stausholm, Erik Spillum, Grith Hagel, Klaus Qvortrup, Ole Thastrup, Henrik Harling, Harry Mellor, Jacob Thastrup, Christina L. Addison PLOS ONE.2021; 16(7): e0253258. CrossRef
[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer Rohini Sharma, Pablo Oriol Valls, Marianna Inglese, Suraiya Dubash, Michelle Chen, Hani Gabra, Ana Montes, Amarnath Challapalli, Mubarik Arshad, George Tharakan, Ed Chambers, Tom Cole, Jingky P. Lozano-Kuehne, Tara D. Barwick, Eric O. Aboagye European Journal of Nuclear Medicine and Molecular Imaging.2020; 47(5): 1239. CrossRef
Combination of DCE‐MRI and DWI in Predicting the Treatment Effect of Concurrent Chemoradiotherapy in Esophageal Carcinoma Changmin Liu, Roger Sun, Jing Wang, Fangling Ning, Zhenbo Wang, Judong Luo, Shaoshui Chen, Shuanghu Yuan, Enzo Terreno BioMed Research International.2020;[Epub] CrossRef
Colorectal cancer: Parametric evaluation of morphological, functional and molecular tomographic imaging Pier Paolo Mainenti, Arnaldo Stanzione, Salvatore Guarino, Valeria Romeo, Lorenzo Ugga, Federica Romano, Giovanni Storto, Simone Maurea, Arturo Brunetti World Journal of Gastroenterology.2019; 25(35): 5233. CrossRef
Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients Matteo Morotti, Prashanth Hari Dass, Adrian L. Harris, Simon Lord European Journal of Drug Metabolism and Pharmacokinetics.2018; 43(2): 137. CrossRef
Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial Loïc Lebellec, François Bertucci, Emmanuelle Tresch-Bruneel, Isabelle Ray-Coquard, Axel Le Cesne, Emmanuelle Bompas, Jean-Yves Blay, Antoine Italiano, Olivier Mir, Thomas Ryckewaert, Yves Toiron, Luc Camoin, Anthony Goncalves, Nicolas Penel, Marie-Cécile BMC Cancer.2018;[Epub] CrossRef
Functional Parameters Derived from Magnetic Resonance Imaging Reflect Vascular Morphology in Preclinical Tumors and in Human Liver Metastases Pavitra Kannan, Warren W. Kretzschmar, Helen Winter, Daniel Warren, Russell Bates, Philip D. Allen, Nigar Syed, Benjamin Irving, Bartlomiej W. Papiez, Jakob Kaeppler, Bosjtan Markelc, Paul Kinchesh, Stuart Gilchrist, Sean Smart, Julia A. Schnabel, Tim Mau Clinical Cancer Research.2018; 24(19): 4694. CrossRef
Dynamic Contrast-Enhanced Ultrasound of Colorectal Liver Metastases as an Imaging Modality for Early Response Prediction to Chemotherapy Marie Mogensen, Martin Hansen, Birthe Henriksen, Thomas Axelsen, Ben Vainer, Kell Osterlind, Michael Nielsen Diagnostics.2017; 7(2): 35. CrossRef
Nano-sized and other improved reporters for magnetic resonance imaging of angiogenesis Simonetta Geninatti Crich, Enzo Terreno, Silvio Aime Advanced Drug Delivery Reviews.2017; 119: 61. CrossRef